Nuwellis (Nasdaq: NUWE) priced a public offering of 20,000,000 shares of common stock (or pre-funded warrants) with accompanying warrants for expected gross proceeds of about $6 million at $0.30 per share and accompanying warrants.
The deal includes Series C and Series D warrants, each with a $0.30 exercise price and five-year term after required stockholder approval and a reverse stock split. The offering includes up to 60,000,000 Series C warrants and 20,000,000 Series D warrants. In a concurrent private placement, Nuwellis agreed to reprice certain existing warrants to a $0.30 exercise price, subject to stockholder approval.
Loading...
Loading translation...
Positive
Approximately $6 million gross proceeds from priced public offering
Series C and D warrants have $0.30 exercise price aligned with offering
Concurrent warrant repricing may incentivize exercise at unified $0.30 level
Negative
20,000,000 new shares plus up to 80,000,000 warrants imply significant dilution
Warrant exercises and repricing at $0.30 could pressure share value
Exercise of new and repriced warrants depends on stockholder approval and reverse split
News Market Reaction – NUWE
-61.21%2.3x vol
25 alerts
-61.21%Session close to close
-65.0%Trough in 2 hr 25 min
$1.16MMarket Cap
2.3xRel. Volume
In the Jun 5 session, NUWE declined 61.21%, reflecting a significant negative market reaction.
Argus tracked a trough of -65.0% from its starting point during tracking.
Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.
Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.
The stock dropped -61.2% in the session following this news. A negative reaction despite the needed ...
Analysis
The stock dropped -61.2% in the session following this news. A negative reaction despite the needed capital fits the historical pattern, where offering-related news averaged a -17.21% one-day move. The structure pairs low-priced shares with long-dated, resettable warrants, and sits alongside an effective S-3 that could bring up to $28 million from warrant exercises. Such layered issuance risk has often pressured Nuwellis’ stock around past financings.
Key Figures
Gross proceeds:$6 millionShares offered:20,000,000 sharesOffering price:$0.30 per share+5 more
8 metrics
Gross proceeds$6 millionPublic offering of common stock and warrants
Shares offered20,000,000 sharesCommon stock (or pre-funded warrants) in offering
Offering price$0.30 per sharePublic offering price per share and accompanying warrants
Series C warrants60,000,000 warrantsSeries C Warrants to purchase common stock
Series D warrants20,000,000 warrantsSeries D Warrants to purchase common stock
Warrant exercise price$0.30Exercise price for Series C and Series D Warrants
Warrant term5 yearsExercise period after stockholder approval and reverse split effectiveness
S-1 file number333-296198Registration statement for this offering
$2.0M registered direct with 5-year warrants under Nasdaq at-the-market rules.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Equity and warrant financings have usually coincided with negative one-day moves, with only one prior offering showing a sharp positive reaction.
Recent Company History
Over the last year, Nuwellis has repeatedly relied on equity and warrant offerings, including deals of $5.1M, $5.0M, $4.3M, $2.0M and a $916,000 registered direct. These transactions often paired common stock or pre-funded warrants with multi-year warrants at low exercise prices. Price reactions were typically negative, reflecting dilution concerns, though the June 10, 2025 closing of a $5.0M deal produced a strong positive move. Today’s $6M offering continues this financing pattern.
Key Terms
pre-funded warrants, warrants, volume weighted average price, reverse stock split, +4 more
8 terms
pre-funded warrantsfinancial
"20,000,000 shares of its common stock ("Common Stock") (or pre-funded warrants in lieu thereof)"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
warrantsfinancial
"with accompanying warrants to purchase common stock for gross proceeds"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
"90% of the lowest daily volume weighted average price for the five trading days"
The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.
reverse stock splitfinancial
"following the receipt of stockholder approval, as required ... and the effective date of a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
zero cash exercisefinancial
"The Series D Warrants include a zero cash exercise option allowing holders"
A zero cash exercise is a way for an option holder to convert stock options into actual shares without paying money up front, typically by surrendering some of the newly issued shares to cover the exercise cost and taxes. Think of it like trading part of a purchased item back to the seller to settle the bill; for investors it matters because it increases the number of shares outstanding, which can dilute existing ownership and affect metrics like earnings per share and potential selling pressure.
Form S-1regulatory
"pursuant to a registration statement on Form S-1 (File No. 333-296198), as amended"
A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.
Rule 462(b)regulatory
"an additional registration statement on Form S-1 filed pursuant to Rule 462(b)"
Rule 462(b) is an SEC provision that lets an issuer add more securities of the same class to an already-effective registration statement by filing a short post-effective amendment that becomes effective on filing, so the additional securities are immediately registered without redoing the full approval process. For investors this matters because it lets companies and underwriters expand an offering quickly—like adding extra seats to a sold-out show—changing supply and potential dilution that can affect the stock price.
Nasdaqregulatory
"as required by the applicable rules and regulations of Nasdaq and the effective date"
The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a public offering of 20,000,000 shares of its common stock ("Common Stock") (or pre-funded warrants in lieu thereof) with accompanying warrants to purchase common stock for gross proceeds of approximately $6 million (the “Offering”).
The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants.
Each of the Series C Warrants and Series D Warrants has an exercise price of $0.30 and will be exercisable for a period of five years following the receipt of stockholder approval, as required by the applicable rules and regulations of Nasdaq and the effective date of a reverse stock split. The Series C Warrants contain a one-time reset of the exercise price in the event that the Company implements a reverse stock split to the greater of: (i) 20% of the combined public offering price per share of Common Stock and accompanying warrants in this offering and (ii) 90% of the lowest daily volume weighted average price for the five trading days immediately following the date of the implementation of a reverse stock split. The Series D Warrants include a zero cash exercise option allowing holders of a Series D Warrant the right to receive, without payment of any additional cash to the Company, an aggregate number of shares equal to the number of shares of Common Stock that would be issuable upon a cash exercise of such Series D Warrant. The offering consisted of to purchase up to 60,000,000 Series C Warrants to purchase of Common Stock and 20,000,000 Series D Warrants to purchase up to shares of Common Stock.
In a concurrent private placement, the Company entered into warrant reprice transactions with certain of its existing warrant holders to amend previously issued Company common stock purchase warrants to reduce their exercise price to $0.30. The exercise of the applicable warrants will be subject to approval of the Company’s stockholders (the “Warrant Reprice Transaction”).
Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent in connection with the Offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-296198), as amended, that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on June 4, 2026 and an additional registration statement on Form S-1 filed pursuant to Rule 462(b), which was filed on June 5, 2026 and became effective upon filing. Electronic copies of the final prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering is being made solely by means of a prospectus. A final prospectus relating to this offering was filed by Nuwellis with the SEC.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the receipt of stockholder approval to permit the exercise of the Series C Warrants and Series D Warrants, the satisfaction of customary closing conditions related to the Offering, the expected closing date of the Offering, the amount and expected use of the net proceeds from the Offering and the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
What are the key terms of Nuwellis (NASDAQ: NUWE) $6 million public offering announced June 5, 2026?
Nuwellis priced a public offering for about $6 million, selling 20,000,000 common shares (or pre-funded warrants) with accompanying warrants at $0.30 per share and warrants. According to Nuwellis, the transaction combines equity and long-dated warrants in a single unit structure.
How many shares and warrants are included in the June 2026 Nuwellis NUWE offering?
The offering covers 20,000,000 shares of common stock (or pre-funded warrants) plus accompanying warrants. According to Nuwellis, it includes up to 60,000,000 Series C warrants and 20,000,000 Series D warrants, each potentially exercisable for common stock after required approvals.
What are the exercise price and term of Nuwellis NUWE Series C and Series D warrants?
Both Series C and Series D warrants have a $0.30 exercise price and a five-year term. According to Nuwellis, they become exercisable after stockholder approval under Nasdaq rules and the effective date of a reverse stock split tied to this financing.
How do the reset and zero-cash features work in Nuwellis NUWE June 2026 warrants?
Series C warrants include a one-time exercise price reset after any reverse split, based on post-split trading prices. According to Nuwellis, Series D warrants allow a zero cash exercise, letting holders receive shares without paying additional cash to the company.
What is the warrant reprice transaction in Nuwellis (NUWE) June 2026 financing?
In a concurrent private placement, Nuwellis agreed to amend certain existing warrants, reducing their exercise price to $0.30. According to Nuwellis, exercise of these repriced warrants is subject to stockholder approval, aligning them with the new offering’s pricing.
How might the June 2026 Nuwellis NUWE equity and warrant offering affect existing shareholders?
The financing brings in about $6 million but adds 20,000,000 shares and up to 80,000,000 warrants. According to Nuwellis, these new and repriced warrants could significantly increase the share count over time if exercised, diluting existing holdings.
